Iterum Therapeutics Announces Japanese Patent Office Decision to Grant Patent Covering Sulopenem Combination, Expiring in 2041
I'm PortAI, I can summarize articles.
Iterum Therapeutics announced that the Japanese Patent Office has decided to grant a patent for Japanese Patent Application No. 2022-554381. The patent covers a combination of sulopenem etzadroxil, probenecid, and valproic acid for treating specified diseases and is expected to expire in March 2041. This news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments